A single-amino acid substitution in the adaptor LAT accelerates TCR proofreading kinetics and alters T-cell selection, maintenance and function
- PMID: 36914891
- PMCID: PMC10063449
- DOI: 10.1038/s41590-023-01444-x
A single-amino acid substitution in the adaptor LAT accelerates TCR proofreading kinetics and alters T-cell selection, maintenance and function
Abstract
Mature T cells must discriminate between brief interactions with self-peptides and prolonged binding to agonists. The kinetic proofreading model posits that certain T-cell antigen receptor signaling nodes serve as molecular timers to facilitate such discrimination. However, the physiological significance of this regulatory mechanism and the pathological consequences of disrupting it are unknown. Here we report that accelerating the normally slow phosphorylation of the linker for activation of T cells (LAT) residue Y136 by introducing an adjacent Gly135Asp alteration (LATG135D) disrupts ligand discrimination in vivo. The enhanced self-reactivity of LATG135D T cells triggers excessive thymic negative selection and promotes T-cell anergy. During Listeria infection, LATG135D T cells expand more than wild-type counterparts in response to very weak stimuli but display an imbalance between effector and memory responses. Moreover, despite their enhanced engagement of central and peripheral tolerance mechanisms, mice bearing LATG135D show features associated with autoimmunity and immunopathology. Our data reveal the importance of kinetic proofreading in balancing tolerance and immunity.
© 2023. The Author(s).
Conflict of interest statement
A.M. is a cofounder of Arsenal Biosciences, Spotlight Therapeutics and Survey Genomics. A.M. serves on the board of directors at Spotlight Therapeutics and Survey Genomics and is board observer at Arsenal Biosciences. A.M. is a member of the scientific advisory boards of Arsenal Biosciences, Spotlight Therapeutics, Survey Genomics and NewLimit. A.M. owns stock in Arsenal Biosciences, Spotlight Therapeutics, NewLimit, Survey Genomics, PACT Pharma and Merck. A.M. has received fees from Arsenal Biosciences, Spotlight Therapeutics, NewLimit, 23andMe, PACT Pharma, Juno Therapeutics, Trizell, Vertex, Merck, Amgen, Genentech, AlphaSights, Rupert Case Management, Bernstein and Analytical, Life Science & Diagnostics Association (ALDA). A.M. is an investor in and informal adviser to Offline Ventures and a client of EPIQ Capital Group. The A.M. laboratory has received research support from Juno Therapeutics, Epinomics, Sanofi, GlaxoSmithKline, Gilead and Anthem. D.Z. has a consulting agreement and research collaboration agreement with Pieris Pharmaceuticals. A.W. is a cofounder and consultant of Nurix Therapeutics. A.W. is on the scientific advisory boards at BlueSphere Bio, BridGene Biosciences, Genentech, Jasper Therapeutics and Soteria Biotherapeutics. He receives consulting fees and has received stock options or owns stock in these companies. The other authors declare no competing interests.
Figures
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
